Nephroblastoma, or Wilms tumor, is the most common malignant kidney tumor in children, accounting for 5 to 10% of pediatric cancers 1. In developed countries, survival rates exceed 90% thanks to multimodal treatment protocols established by the International Society of Pediatric Oncology (SIOP) and the National Wilms Tumor Study Group (NWTSG) 2,3. In sub-Saharan Africa, the management of this disease faces specific challenges related to diagnostic delays, socio-economic constraints, and limited access to specialized care 4,5. The Franco-African Pediatric Oncology Group (GFAOP) has initiated the adaptation of SIOP protocols to the African context, demonstrating their feasibility and effectiveness 6,7. Our study aims to evaluate the experience of the Thiès Regional Hospital Center in the management of nephroblastoma by analyzing epidemiological, therapeutic, and prognostic aspects in a decentralized healthcare context similar to the challenges reported in other developing countries 8.
M et al. (Thu,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: